Tranexamic acid,
does it really help with Reduced death due to bleeding when given within three hours of birth for clinically diagnosed postpartum hemorrhage?
research showsTranexamic acid is rated A because a very large randomized trial showed fewer deaths due to bleeding when it was given intravenously within three hours of birth for clinically diagnosed postpartum hemorrhage. WOMAN randomized 20,060 participants; bleeding death was 1.5% versus 1.9%, RR 0.81 (95% CI 0.65 to 1.00), and among those treated within three hours it was 1.2% versus 1.7%, RR 0.69 (95% CI 0.52 to 0.91). Hysterectomy and the overall composite were not reduced, but this verdict specifically targets death from bleeding, and WHO strongly recommends intravenous treatment as soon as possible within three hours of birth. Thrombosis, seizures, and other harms are assessed separately under safety.
ads claimThis evidence should not be expanded into routine prophylaxis for every birth or equal benefit when treatment begins after three hours. WOMAN directly studied early treatment of already diagnosed postpartum hemorrhage, and tranexamic acid does not replace uterotonics, fluids, source evaluation, transfusion, or surgery.
Useful facts when choosing a product
- Tranexamic acid is a prescription antifibrinolytic that limits fibrin clot breakdown and is administered intravenously for postpartum hemorrhage.
- The WOMAN regimen and WHO guidance use 1 g over ten minutes as soon as possible within three hours of birth, with one additional 1-g dose if bleeding continues after 30 minutes or restarts within 24 hours.
- The large trial did not show more thromboembolic events, but thromboembolic contraindications and renal function require review, and seizure risk can rise with high doses.
- Accidental intrathecal injection after confusion with obstetric spinal-anesthetic ampoules can cause fatal neurotoxicity, making storage, labeling, and route verification essential.
What the research actually shows
The WOMAN Trial Collaborators randomized 20,060 women with clinically diagnosed postpartum hemorrhage at 193 hospitals in 21 countries to intravenous tranexamic acid 1 g or placebo. Death due to bleeding fell with an overall RR of 0.81 and an RR of 0.69 when treatment began within three hours of birth. Hysterectomy was not reduced, RR 1.02, and adverse events including thromboembolic events did not differ significantly. Later clinical review and WHO guidance support giving 1 g as soon as possible within three hours of birth, with one additional 1-g dose if bleeding continues after 30 minutes or restarts within 24 hours.
Why this is classified as A (95)
The 20,060-participant WOMAN trial showed a direct mortality endpoint, RR 0.81 for bleeding death overall and 0.69 within three hours, converging with a strong WHO recommendation for early intravenous use. This supports A with 95 points. Null hysterectomy and overall composite results are confined to those subclaims, while thrombosis, high-dose seizures, and wrong-route errors remain separate safety issues.
Counterpoint. This verdict concerns emergency treatment of clinically diagnosed postpartum hemorrhage, not routine prophylaxis. Benefit diminishes with delay, so medication preparation, diagnosis, and the full standard-care response should proceed rapidly and together.
Rejudgment record. New verdict — Applied A for the direct hard mortality endpoint in the 20,060-participant international randomized double-blind WOMAN trial, including RR 0.81 for bleeding death and RR 0.69 when given within three hours, the coherent time effect, and strong WHO guidance, while separating the null hysterectomy result as its own subclaim
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced death due to bleeding in clinically diagnosed postpartum hemorrhage | A | In 20,060 WOMAN participants, bleeding death was 1.5% versus 1.9%, RR 0.81. |
| Reduced bleeding death with early treatment within three hours of birth | A | With treatment within three hours, the direct mortality endpoint was 1.2% versus 1.7%, RR 0.69. |
| Reduced hysterectomy in postpartum hemorrhage | D | Hysterectomy was not reduced, at 3.6% versus 3.5%, RR 1.02. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| WOMAN Trial Collaborators. 2017 | International randomized double-blind placebo-controlled trial | 20,060 | London School of Hygiene & Tropical Medicine, Pfizer, UK Department of Health, Wellcome Trust, and Bill & Melinda Gates Foundation | Death due to bleeding, hysterectomy, composite death or hysterectomy, and thromboembolic events | Bleeding-death RR 0.81 (95% CI 0.65 to 1.00); within three hours RR 0.69 (95% CI 0.52 to 0.91); hysterectomy RR 1.02. | Very large randomized trial with a direct mortality endpoint |
| Brenner A, Ker K, Shakur-Still H, Roberts I. 2019 | Clinical evidence review of tranexamic acid for postpartum hemorrhage | Academic review authored by WOMAN investigators | Bleeding death, treatment effect within three hours, and thromboembolic safety | Summarized the WOMAN RR of 0.69 within three hours, no increase in thromboembolic events, and WHO guidance for early 1-g intravenous treatment. | Supportive evidence for timing and clinical implementation |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-22).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-22 · Corrections: none
Cite this verdict
[Chamgap] Tranexamic acid x reduced bleeding death when given within three hours for postpartum hemorrhage — Evidence Grade A·95. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/tranexamic-acid-postpartum-hemorrhage-bleeding-death/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.